FinnGen is one of the very first personalized medicine projects at this scale and brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks and international pharmaceutical companies and hundreds of thousands of Finns.
The FinnGen study will construct a unique resource of 500 000 Finns that enables ambitious study designs to improve our understanding of the genetic background of diseases and subsequently for implementation of genome medicine in clinical practice and drug development. FinnGen aims on one hand to provide useful and exciting new data but also construct a world-class resource that can be applied for future studies that combine genetic and health data in a way that is currently not possible on this scale.
The FinnGen project is an academic-pharma partnership that involves nine Finnish biobanks, all Finnish University Hospitals and their respective Universities, the Institute of Health and Welfare (THL), the Finnish Red Cross Blood Service and nine large pharmaceutical companies (Abbvie, AstraZeneca, Biogen, Celgene, Genentech, GSK, Merck/MSD, Pfizer and Sanofi) to develop the potential of these resources to serve medicine.
Thanks to the unique cooperation model, immense potential of the Finnish research environment for genetic studies and the favorable progress of the study during the first year, FinnGen has been found as an attractive opportunity by many pharmaceutical companies
Health & Wellbeing, Invest in Finland